Therapeutic gene expression in glial cells has been tested for the treatment of neurological diseases in animal models. Many of such studies used the promoter of the glial fibrillary acidic protein (GFAP) to restrict gene expression to astrocytes. We have investigated in the current study whether it is possible to improve the transcriptional activity of the cellular promoter, while maintaining its cell-type specificity. We constructed an expression cassette containing a hybrid cytomegalovirus (CMV) enhancer/GFAP promoter and placed it into baculovirus vectors, a type of viral vectors capable of transducing astrocytes. In another vector design, we used inverted terminal repeats (ITRs) from adeno-associated virus (AAV) to flank the expression cassette. The recombinant baculoviruses with the hybrid promoter improved gene expression levels over two orders of magnitude in glial cell lines and by 10-fold in the rat brain when compared to the baculoviruses with the GFAP promoter alone. The expression was further improved by ITR flanking, reaching levels higher than that mediated by the baculovirus vectors with the CMV immediate-early enhancer/ promoter (CMV promoter). Using these recombinant baculoviruses, we observed extended in vivo transgene expression in the rat brain at 90 days postinjection, by which time the gene expression from baculovirus vectors with the GFAP or CMV promoter had already become undetectable. The astrocyte specificity of the GFAP promoter was preserved in the engineered expression cassette with the CMV enhancer and the AAV ITRs, as demonstrated by immunohistological analysis of brain samples and an axonal retrograde transport assay. Taken together, our findings suggest that these baculovirus vectors may serve as useful tools for astrocyte-specific gene expression in the brain.
Introduction
Astrocytes, the most abundant glial cells in the central nervous system (CNS), play a crucial role in supporting the survival and physiological functions of neurons. The importance of using these cells as gene transfer targets to express molecules of therapeutic interest in the CNS for the treatment of neuronal diseases and disorders has recently been demonstrated and discussed. [1] [2] [3] Neurotrophic factors secreted by astrocytes in the CNS may act locally on nearby neurons and support their functions like those that are produced in a peripheral target region and act through the classical mechanism of retrograde transport. Under the pathological conditions that affect axonal transport, the physiological functions of the neurotrophic factors produced by target tissues will be hampered or even totally blocked. Besides, the affected neurons could have become vulnerable to viral infection or overexpression of a transgene. Gene transfer into astrocytes in close proximity to neuronal perikarya does not require axonal transport for neurotrophic factors to reach cell soma. The produced trophic factors can function in a paracrine mode to sustain the survival of the neurons, slow down or stop the degeneration processes of concerned axons and probably also stimulate axonal regeneration. Moreover, gene transfer into astrocytes with neurotrophic factors might reduce gliosis, benefiting astrocytes-neuronal cell-cell interactions. 1 Among the various gene delivery vectors that are capable of transducing glial cells is the baculovirus Autographa californica multiple nucleopolyhedrovirus (AcMNPV)-based vectors, recently emerging as a new type of gene therapy vehicles. [4] [5] [6] [7] [8] Baculoviruses infect astrocytes after being injected into the brain. 6, 9 It is worth noting that the brain injection does not offer cell-type specificity: in addition to astrocytes, other types of cells in the brain, including neurons, can be transduced by the injected baculoviruses. 6, [9] [10] [11] To restrict transgene expression to astrocytes, the promoter of the glial fibrillary acidic protein (GFAP) has been widely used. 12 With its cellular authentic sequence, the promoter is less sensitive to promoter silencing as compared to viral promoters, thus being potentially useful for long-term expression. 13 However, like many other cellular promoters, the GFAP promoter displays a weaker transcriptional activity when compared to those commonly used strong promoters derived from viruses, for example, the cytomegalovirus immediate-early enhancer/promoter (CMV promoter). 14, 15 We had previously adopted a hybrid promoter approach to improve the transcriptional activity of a neuron-specific promoter by appending the CMV enhancer 5 0 to the cellular promoter. 16 Our hybrid promoter, after being placed into plasmid, adeno-associated virus (AAV) and baculovirus vectors, functioned preferentially in neurons over glial cells and was effective in improving the levels of transgene expression and prolonging gene expression in neurons. 9, 11, 17, 18 Another reported approach useful to the improvement of transgene expression is flanking an expression cassette of interest with the inverted terminal repeats (ITRs) of AAV. Several groups have modified their viral or plasmid vectors with this approach and reported the improved efficiency of gene expression in mammalian cells, [19] [20] [21] [22] [23] [24] [25] Xenopus embryos 26 and fishes. 27, 28 For this study, we constructed recombinant baculovirus vectors accommodating the GFAP promoter and set out to investigate whether the above two approaches, in particular when the CMV enhancer and the AAV ITRs were used together, could improve transgene expression in an astrocyte-specific manner. Our results demonstrated the preserved cellular specificity of the GFAP promoter after the CMV enhancer sequence was inserted and the expression cassette flanked by the ITRs. Moreover, we showed that gene expression from the newly developed baculovirus vectors was significantly improved.
Results

Improved transgene expression in cultured cells
To test whether the CMV enhancer could improve the strength of the GFAP promoter, we first constructed plasmid vectors and tested them in cultured glial cells. The gene regulatory elements from pDRIVE02-GFAP containing a rat GFAP promoter and pRc/CMV 2 containing the enhancer/promoter sequences of the immediate-early gene of the human CMV were cloned into the pGL3 luciferase reporter vector. Four types of plasmid vectors were constructed to contain (1) the GFAP promoter (pGFAP), (2) a hybrid promoter with the CMV enhancer inserted upstream of the GFAP promoter (pCMV E/GFAP), (3) a hybrid promoter with two copies of the CMV enhancer upstream of the GFAP promoter (p2 Â CMV E/GFAP) and (4) the CMV immediate-early enhancer/promoter (pCMV). The luciferase expression levels from the four plasmid vectors were compared following transfection of primary glial cells isolated from the rat cortices and U251 human astrocytoma cells by polycation polyethylenimine (PEI). As shown in Figure 1 , pCMV E/GFAP improved gene expression levels by 100-fold when compared to pGFAP. The levels were only slightly lower than those driven by the CMV promoter, one of the most robust transcriptional control elements identified thus far. After the addition of a second copy of the CMV enhancer, the levels of expression were, however, reduced notably in both primary glial cells and U251 cells.
We then constructed recombinant baculovirus vectors by inserting into the transfer vector pFastBac1 the reporter gene encoding firefly luciferase under the control of the CMV, GFAP or CMV E/GFAP promoter and named them BV-CMV, BV-GFAP and BV-CMV E/GFAP, respectively ( Figure 2 ). The fourth expression cassette was constructed by flanking the luciferase gene and the hybrid CMV E/GFAP promoter with the AAV ITR sequences. The generated chimeric AAV/baculovirus vector was named BV-CMV E/GFAP-ITR ( Figure  2 ). To evaluate the transduction efficiency of baculovirus in astrocytes, primary rat glial cells and three glial cell lines, rat C6, human U251 and BT325, were infected with BV-CMV at a multiplicity of infection (MOI) of 50 plaqueforming units (PFU) of viral particles per cell and the double immunostaining of the infected cells was carried out using antibodies against luciferase to show transduced cells and antibodies against GFAP to visualize astrocytes. The immunochemical colocalization of the two proteins in these cells was easily detected ( Figure  3a) , with 60-80% of GFAP-positive cells being transduced by baculoviruses. We then compared the gene expression levels from the above four types of recombinant baculovirus vectors using a quantitative luciferase activity assay after C6, U251 and BT325 cells were infected at a viral MOI of 50. Similar to that observed in the study using plasmid vectors, the CMV enhancer in the context of baculovirus increased the strength of the 
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GFAP promoter by 10-to 100-fold in different cell lines tested, resulting in levels of gene expression close to those driven by the CMV enhancer/promoter ( Figure 3b ). With AAV ITR flanking, further improvement in gene expression was observed. BV-CMV E/GFAP-ITR increased the expression by at least 10-fold relative to BV-CMV E/GFAP, reaching the levels even higher than those provided by BV-CMV (Figure 3b ). To test whether the CMV enhancer and the AAV ITR sequences could prolong transgene expression, an in vitro time-course study was carried out in C6, U251 and BT325 cells. Cell samples were collected for luciferase activity assays 1, 3 and 7 days after the infection using BV-CMV, BV-CMV E/GFAP or BV-CMV E/GFAP-ITR at a viral MOI of 50. As shown in Figure 3c , among the three viral vectors tested, BV-CMV E/GFAP-ITR was the best, providing the highest levels of gene expression at all time points in the three cell lines, although the levels dropped slightly over time. BV-CMV E/GFAP infection resulted in lower levels of transgene expression in two cell lines than BV-CMV infection initially but the expression levels became much higher than those provided by BV-CMV by day 7. The levels of gene expression from BV-CMV changed obviously as a function of time, decreasing over almost two orders of magnitude within 7 days.
Improved transgene expression in the brain
To determine whether the enhanced and extended gene expression in cultured glial cells mediated by our baculovirus vectors could be reproduced in vivo, we examined viral transduction in the rat brain after stereotaxical injection of the baculovirus vectors into the striatum. Firstly, we assessed the dose-dependent transduction efficiency of BV-CMV E/GFAP-ITR, the viral vector displaying the highest transduction efficiency in vitro (Figure 4a ). Four doses of BV-CMV E/GFAP-ITR, increased by order of magnitude from 1 Â 10 6 to 1 Â 10 9 PFU of viral particles per brain, were injected and brain tissues were collected 2 days later for luciferase activity assay. A sharp increase in transgene expression, close to two orders of magnitude, was detected when the doses increased from 1 Â 10 6 to 1 Â 10 8 PFU per brain, followed by a moderate increase at the dose above 1 Â 10 8 PFU per brain. This finding confirmed that the baculoviruses with the GFAP promoter were able to infect brain cells effectively.
We then compared the dynamics of gene expression mediated by baculovirus vectors with four different types of expression cassettes in a 90-day time-course study ( Figure 4b) . A low dose of 5 Â 10
7 PFU per brain was tested in order to exploit the opportunity of detecting possible decreases in transgene expression within the experimental period. A low dose may also minimize the influence of upregulation of transcription factors by a concentrated viral preparation, which might activate the endogenous GFAP promoter. 29 BV-CMV mediated an initially high but sharply dropping luciferase expression, which was undetectable at 90 days. As observed in vitro, BV-GFAP performed poorly also in the brain, mediating a low level of initial expression, which became undetectable after 30 days. With the assistance of the CMV enhancer, luciferase expression levels increased by 10-fold in the BV-CMV E/GFAP-infected brain. The levels decreased over time as well but at a much slower rate in comparison to that of BV-CMV or BV-GFAP. With the ITR flanking of the expression cassette containing the hybrid CMV E/GFAP promoter, further improvement in gene expression was noticeable. The infection with this virus resulted in 10 times higher levels of luciferase expression when compared to the BV-CMV E/GFAP infection. The superior performance of BV-CMV E/GFAP-ITR over BV-CMV E/GFAP was maintained through the whole experimental period, although the luciferase expression level also decreased time-dependently.
Astrocyte-specific expression in the brain
One of the critical issues in developing a hybrid promoter is whether the original cellular specificity of a cell-type promoter could be preserved after promoter engineering. We investigated the issue using two independent approaches. Firstly, immunohistochemical double staining was carried out. Two days after injection of 5 ml (1 Â 10 9 PFU of viral particles per brain) of either BV-CMV E/GFAP or BV-CMV E/GFAP-ITR into the rat striatum, brain tissue sections were collected for double-immunostaining, using anti-luciferase antibodies to visualize transducted cells, anti-GFAP antibodies or anti-neuronal nuclei protein (NeuN) antibodies to show astrocytes or neurons. By double staining for the luciferase and GFAP proteins in the BV-CMV E/GFAPinfected brain tissues collected from the regions around the injection site, we observed that luciferase expression was almost exclusively in astrocytes. Among a total of 564 cells stained positively with the anti-luciferase antibody, 525 of them were simultaneously stained positively with the GFAP antibody. In the case of using As an attached transgene could affect the cellular specificity of the GFAP promoter, 12 we constructed and tested another baculovirus vector with a CMV E/GFAP-ITR expression cassette in which an EGFP gene was used instead of the luciferase reporter gene. EGFP expression in the brain section without immunostaining was easily detectable ( Figure  5h ). Immunohistochemical staining using antibodies against GFAP demonstrated that these EGFP-positive cells were also GFAP-positive (Figure 5g-i) .
We previously demonstrated that baculoviruses, after being internalized by nerve terminals at an injection site, could migrate by axonal transport to neuronal cell bodies in a remote region. 9 This feature provides a unique opportunity to study gene expression in neurons, as gene expression detected in a region remote from the injection site would be pure neuronal gene expression as a consequence of the axonal transport of baculovirus vectors. This viral transport mechanism was used in the current study to examine the cell-type specificity of the newly developed vectors containing the GFAP promoter, by analyzing gene expression in the striatum (the injection site) and in the cerebral cortex, a remote region where many neurons have long axons projecting to the striatum ( Figure 6 ). The luciferase expression from BV-CMV was detected mainly at the injection site, with 85% of total expression in the striatum and 15% in the cerebral cortex, indicating some activity of the CMV promoter in cerebral cortex neurons. A baculovirus vector with a neuron-specific promoter, 9 included here as a positive control, provided a high level of luciferase GFAP promoter in baculovirus vectors CY Wang and S Wang expression, around 68% of total value, in the remote region. When the two baculovirus vectors containing the GFAP promoter, BV-CMV E/GFAP and BV-CMV E/GFAP-ITR, were tested, extremely low levels of expression were detected in the cerebral cortex. As some leakage of viral vectors in the cerebral cortex during striatum injection was possible, this low-level expression could be owing to transduction of the leaked viral vectors into astrocytes in the cerebral cortex. This was confirmed by the observation that when the cerebral cortex was dissected into the part near the injection site and the rest, the luciferase activity was detected only in the tissue around the injection site (data not shown). These findings, together with immunohistochemical staining results, suggested strongly that the two baculovirus vectors containing the GFAP promoter developed in this study did not display significant transcriptional activity in neurons.
Discussion
Being insect viruses, baculoviruses are unable to replicate and express viral proteins in mammalian cells, [4] [5] [6] [7] [8] thus significantly reducing the chance of pre-existing antiviral humoral and cellular immunity in mammals.
Other inherited advantages of using these viruses as gene therapy vectors include the lack of obvious cytopathic effects, a broad tropism in both proliferating and non-proliferating cells, large cloning capacity and the easy preparation of large quantities of viruses with high titers.
Astrocytic specificity
Baculoviruses can infect several types of cells in the CNS.
6,9,10
An initial report described the efficient transduction of baculoviruses into neuroepithelial, neuroblastic and glial cells in the primary cell cultures of human embryonic brains and mainly into astrocytes in the mouse brain. 6 Another study identified the cuboidal epithelial cells of the choroids plexus as the main type of target cells for baculovirus infection, with modest gene expression being detected in endothelial cells but very limited or no expression found in other types of brain cells, including neurons and astrocytes. 10 In our previous study using Cy3-labeled baculoviruses in the rat brain, although the viruses were more prone to infecting astrocytes than others, they were capable of infecting neurons, with approximately 30% of the transduced cells in the brain being identified as neurons. 9 These findings have underlined the importance of controlling the delivery of baculovirus vectors and/or the gene expression from the vectors in order to use them in targeted gene therapy through astrocytes.
In the last several years, the specific cellular location of the GFAP protein in the CNS has encouraged the extensive use of a GFAP promoter to target transgene expression to cells of glial origin. 12 Up to now, the astrocyte specificity of transgene expression driven by the GFAP promoter has been reported after using adenovirus, 30 herpes simplex virus (HSV) 31 and lentivirus. 29, 32 However, when using AAV carrying the GFAP promoter, most transduced brain cells appeared neuronal. 33, 34 As the AAV ITR sequences could function directly as a promoter for expression of a reporter gene, 35 overriding the GFAP promoter by AAV ITRs could possibly lead to neuronal expression. 36 This notion is not explicitly supported by the observation from the current study using an expression cassette in which the GFAP promoter has been used together with the AAV ITRs. The present study addressed the cell specificity issue using both astrocytic and neuronal markers, and identified astrocytes as the only type of cells transduced. The possibility of neuronal transduction was further excluded by the findings obtained through unique axonal transport assays. Therefore, it remains an open question as to whether neuronal transduction by AAV with the GFAP promoter is related to its particular viral property. Su et al. 12 recently reported that depending on the transgene integration site and the attached sequence of 
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a targeted gene in transgenic mice, the GFAP promoter could drive transgene expression at a significantly high level in neurons. It appears that the cellular specificity of the GFAP promoter needs to be assessed according to a specific application condition.
In addition to AAV, several other viral vectors may affect the cell/tissue specificity of a cellular promoter that has been inserted into their vector backbone. For example, after a 1.4-kb prostate-specific antigen promoter with the luciferase gene was placed into a firstgeneration adenoviral vector, the tissue specificity of the promoter was decreased by 400-fold. 37 Similarly, a neuron-specific enolase promoter after being placed into HSV-1 vectors and a glial cell-specific JC virus promoter placed into retroviral vectors lose their cell specificity. 38, 39 One possible reason for the loss of the desired specificity could be the powerful endogenous viral transcriptional controls overriding the cellular promoters. 40 Different from animal viruses, baculovirus infection does not lead to expression of its own genes or viral replication in mammalian cells. 4, 41, 42 As a result, even though certain sequences of the virus can function as promoters or enhancers of transcription in insect cells, they will be silent in mammalian cells owing to the absence of supporting factors, and are less likely to have an effect on the cell-type specificity of a mammalian promoter inserted into a baculovirus vector.
Level and duration of transgene expression in astrocytes
Compared to other cellular promoters, the GFAP promoter possesses a moderately high level of activity, capable of driving gene expression representing up to approximately 0.2% of total brain protein. 43 However, in comparison with strong viral promoters, for example the CMV promoter, it is still weak, as demonstrated in the current study and also several other studies. 14, 15 This inherent weakness in driving gene expression might affect the efficacy of certain gene therapy applications in the CNS that require high-level expression of therapeutic genes. Appending a viral transcriptional regulatory element to a cellular promoter has been tried in previous studies to improve its strength. In one of such studies using plasmid vectors, enhancers and promoters from muscle-specific genes were substituted for or combined with the CMV enhancer/promoter and one of these chimeric vectors offered an expression level twice that of the parental plasmid. 44 An AAV-2 vector that uses the CMV enhancer/promoter in combination with a 1.2 kb human skeletal actin promoter increased transgene expression in the muscle significantly, providing a therapeutic range of expression of coagulation factor IX with a two-to fourfold lower vector dose. 45 The most widely used hybrid promoter is probably the CMV Immunohistological analysis of rat brains injected with recombinant baculoviruses. Five microliters (1 Â 10 9 PFU) of BV-CMV E/GFAP-ITR (a-f) or BV-CMV E/GFAP-EGFP-ITR (g-i) was injected into the striatum. Two days after the injection, brain samples were collected and frozen coronal sections of each brain, within 0.5 mm from the injection site, were cut at 30 mm thickness for free-floating immunostaining.
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CY Wang and S Wang enhancer/chicken b-actin promoter (CAG), which can direct improved expression in several tissues. 16, 46 The CMV enhancer also stimulated the elongation factor 1a promoter and the ubiquitin promoter for increased levels of transgene expression. 47, 48 In one of our previous studies attempting to strengthen the activity of the neuronal specific platelet-derived growth factor B-chain (PDGF) promoter, several hundred-fold improvement in vitro and around 10-fold in vivo could be achieved by using the CMV enhancer. 9, 11, 17, 18 The current study further confirms the feasibility of using the approach to stimulate positively an astrocyte-specific promoter. The mechanism underlying the enhancement is not clearly understood yet, but probably related to a favorable interaction between the transcriptional factors and auxiliary proteins attracted by the CMV enhancer and the GFAP promoter.
Incorporating the AAV ITRs into our baculovirus vectors harboring the hybrid CMV enhancer/GFAP promoter leads to further improvement in transgene expression. This finding is consistent with the observations made in Breakefield's lab using HSV-1 amplicon vectors containing the AAV ITRs and many other reports using plasmids containing the AAV ITRs. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The AAV ITRs used in this study, however, appeared to be unable to change the dynamics of transgene expression. With or without the sequences, cultured cells and brain tissues transduced by the baculovirus vectors harboring the hybrid CMV enhancer/GFAP promoter displayed similar patterns of time-dependent decrease in gene expression. Several mechanisms might be responsible for the loss of expression. Baculovirus genomic DNAs remain episomal in transduced cells. They cannot replicate in mammalian cells and would be diluted by cell dividing over time, thus resulting in a decrease in gene expression. This is more likely for in vitro transduction, as cultured cells divide much faster than cells in the brain. Alternatively, baculovirus genomic DNA might activate host cell defense machinery, which would ultimately eliminate the viral vector together with the accommodated gene expression cassette. Although the GFAP promoter is a cellular transcription regulatory element with an authentic DNA sequence and should be less sensitive to promoter silencing, the CMV enhancer part of our hybrid promoter would still be subjected to the regulation of transcriptional silencing such as DNA methylation. A recent publication has reported transcriptional silencing caused by extensive methylation of the CMV promoter and enhancer following adenoviral gene transduction. 49 Nevertheless, the collaborative action of the AAV ITRs and the CMV enhancer significantly augmented initial expression levels, which might have made it possible to detect the prolonged expression of transgene up to 90 days postinjection.
Inverted terminal repeats are crucial AAV elements, serving as primers for host cell-mediated DNA synthesis to convert the single-stranded virion DNA into doublestrand DNA templates for transcription and replication. 50 A number of reports also suggested their roles in mediating a substrate DNA integration into the host DNA and in defining integration boundaries of viral genome. [51] [52] [53] The presence of ITRs appears to be the only requirement for the formation of the episomally stable concatamers of recombinant AAV genome. 54, 55 Longterm transgene expression mediated by AAV vectors was found to be associated with the molecular conversion of single-stranded viral genomes to high-molecular-weight circular concatamers and the prolonged episomal persistence of the concatamers. 54 Further investigations will be needed to clarify whether some of these functions of In conclusion, our findings demonstrate a successful methodology of using viral regulatory elements to strengthen the transcriptional activity of a cellular promoter in the context of baculovirus vectors without changing its cell-type specificity. The baculovirus vectors developed in this study could potentially be useful for gene therapy for neurodegenerative diseases and disorders through astrocytic transduction. They may also prove to be valuable for brain cancer therapy by directing gene expression to glioma cells.
Materials and methods
Construction of expression vectors
Four plasmid vectors were constructed and tested for the effects of the CMV enhancer on the GFAP promoter. To construct the hybrid CMV E/GFAP promoter, a CMV enhancer (CMV E, À568 to À187 relative to the TATA box of the CMV immediate-early promoter) amplified from pRC/CMV 2 (Invitrogen, Carlsbad, CA, USA) was inserted into a pGL3-basic plasmid carrying a luciferase reporter gene (Promega, WI, USA) between the sites of KpnI and SacI, and a rat GFAP promoter was subsequently inserted at the downstream of the CMV E between NheI and HindIII. This rat GFAP promoter was amplified from pDRIVE02-GFAP (InvivoGen, San Diego, CA, USA), with a complete promoter size of 1589 bp. To construct the hybrid promoter with two copies of CMV E, an additional CMV E was inserted into the sites of SacI and NheI. The two CMV enhancers were placed head-to-tail, with only a 6 bp enzyme site between them. Two control plasmid vectors were constructed by inserting the CMV promoter and the GFAP promoter into pGL3-basic plasmid at the sites of KpnI and HindIII, respectively.
To construct recombinant baculovirus vectors, pFastBac1 plasmid (Invitrogen) was used ( Figure 2 ). To generate baculoviruses carrying the hybrid CMV E/GFAP promoter (BV-CMV E/GFAP), a CMV enhancer sequence amplified from pRC/CMV 2 was inserted into pFastBac1 between the sites of NotI and XbaI, and a GFAP promoter amplified from pDRIVE02-GFAP was subsequently inserted at the downstream of the CMV E between XbaI and XhoI. The CMV enhancer/promoter was inserted into pFastBac1 between NotI and XbaI and the GFAP promoter between XbaI and XhoI to generate two control constructs, named BV-CMV and BV-GFAP, respectively. To construct the baculovirus vector with the ITRs from AAV (BV-CMV E/GFAP-ITR), an expression cassette from pAAV plasmid, 18 containing a multiple cloning site, a reporter gene encoding luciferase, an SV40 polyA signal and two ITR sequences at both ends, was amplified and inserted into pFastBac1 between AvrII and SalI. The CMV E/GFAP promoter was then inserted into the sites of KpnI and HindIII. A luciferase reporter gene was used for all vectors and was inserted into the downstream of the promoters, between the sites of XhoI and HindIII. We also constructed a baculovirus vector with a CMV E/GFAP-ITR expression cassette in which an EGFP gene was used instead of the luciferase reporter gene and named it BV-CMV E/GFAP-EGFP-ITR.
Recombinant baculovirus vectors containing the above promoters were produced and propagated in sf9 insect cells according to the manual of the Bac-to-Bac baculovirus expression system (Invitrogen). Budded viruses in the insect cell culture medium were collected and filtered through a 0.45-mm pore size filter (Minipore, Bedford, MA, USA) to remove any contamination, and concentrated by ultracentrifugation at 28 000 g for 60 min. Viral pellets were re-suspended in appropriate volumes of 0.1 M phosphate-buffered saline (PBS) and their infectious titers (PFU) were determined by plaque assay on sf9 cells.
Plasmid transfection and virus infection
For in vitro study, primary glial cell cultures established from the cortices of embryonic Wistar rats at gestational day 20, and glioma cell lines of C6, U251 and BT325 were used. Cells were seeded in 48-well plates with densities of 20 000 cells/well. For plasmid transfection, plasmid DNA was diluted in 5% glucose and PEI (25 kDa; Sigma-Aldrich, San Diego, CA, USA) was prepared as an aqueous stock solution containing 10 mM nitrogen. Complexes were formed at the ratio of 10 equivalents of PEI nitrogen per DNA phosphate by adding the appropriate amount of PEI solution into the DNA solution, briefly mixing by vortexing and incubating for 30 min at room temperature. Ten microliters of the PEI/ DNA complexes containing 0.5 mg plasmid DNA was used to transfect cells in 100 ml of Opti-MEM (Invitrogen) for 3 h at 371C. The medium was then replaced with fresh complete medium and the cells were further incubated at 371C for 24 h before being collected for luciferase activity assay. For baculovirus infection, appropriate amounts of baculovirus vectors were added in 100 ml of serum-free DMEM, and incubated with the cells at 371C for 1 h. After the incubation, the serum-free DMEM containing the viruses was replaced by fresh growth medium, and the cells were collected for luciferase activity assay at the time points indicated in the text.
For in vivo viral infection, adult male Wistar rats (weighing 250-300 g) were used. Five microliters of baculovirus vectors was injected stereotaxically into the striatum at two injection sites (AP 71.0 mm, ML +2.5 mm and DV À5.0 mm from bregma and dura) using a 10 ml Hamilton syringe connected with a 30-gauge needle, at a speed of 0.5 ml/min. The needle remained in place for another 5 min before being slowly retracted. Rats were killed and the brain tissues were collected at the time points indicated in the text.
Luciferase activity assay
For in vitro studies, cells in 48-well plates were washed and permeabilized with 100 ml of reporter cell lysis buffer (Promega). The total protein concentration of each lysate was determined using the DC Protein Assay (Bio-Rad, Hercules, CA, USA). In in vivo studies, tissue samples collected from different brain regions were homogenized in PBS (100 ml PBS per 50 mg tissue) by sonication for 10 s on ice. Homogenized tissues were then centrifuged at 13 000 r.p.m. for 10 min at 41C. Ten microliters of cell extract (in vitro) or supernatant of homogenized tissues (in vivo) were used for luciferase assay with a luciferase assay kit (Promega) in a single-tube luminometer (Berthold Lumat LB 9507, Bad Wildbad, Germany) for 10 s. The results were expressed in relative light units per milligram of total protein (in vitro) or per brain region (in vivo). Luciferase expression data from in vitro and in vivo experiments were analyzed statistically with the Student's t-test.
Immunohistochemistry analysis
Under deep anesthesia, rats were perfused with 0.1 M PBS (pH 7.4) solution followed by 4% paraformaldehyde in PBS. The brains were removed and postfixed in the same fixative for 2-4 h. Cryostat sections were cut at 30 mm thickness for free-floating immune staining. A polyclonal anti-luciferase (Promega, dilution 1:150) and a monoclonal anti-GFAP protein (Chemicon International, USA; dilution 1:150) or a monoclonal anti-neuronspecific nuclear protein (NeuN; Chemicon International, dilution 1:150) was used as primary antibodies. Anti-rabbit IgG TRITC conjugate (Sigma-Aldrich, dilution 1:500) and anti-mouse IgG fluorescence isothiocyanate (FITC) conjugate (Sigma-Aldrich, dilution 1:500) were used as the secondary antibodies. For the rat brain injected with BV-CMV E/GFAP-EGFP-ITR, single staining using the GFAP antibody was carried out as the EGFP protein can be observed without immunostaining. Sections were examined with an Olympus Fluoview 300 confocal laser scanning microscope. Each section was initially scanned with a 488 nm laser line, and an emission filter BP 510-530 for the detection of FITC fluorescein, and then with a 543 nm laser line and an emission filter LP 560 for the detection of TRITC fluorescein.
